Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIRM Stock Forecast 2025-2026
$64.67
Current Price
$3.32B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MIRM Price Targets
+46.9%
To High Target of $95.00
+40.7%
To Median Target of $91.00
+25.2%
To Low Target of $80.94
MIRM Price Momentum
-9.6%
1 Week Change
-9.3%
1 Month Change
+48.3%
1 Year Change
+56.4%
Year-to-Date Change
-17.7%
From 52W High of $78.55
+75.4%
From 52W Low of $36.88
📊 TOP ANALYST CALLS
Did MIRM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mirum Pharma is one of their latest high-conviction picks.
Latest MIRM Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, MIRM has a bullish consensus with a median price target of $91.00 (ranging from $80.94 to $95.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $64.67, the median forecast implies a 40.7% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 46.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIRM Analyst Ratings
10
Buy
0
Hold
0
Sell
MIRM Price Target Range
Low
$80.94
Average
$91.00
High
$95.00
Current: $64.67
Latest MIRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | Baird | Brian Skorney | Outperform | Maintains | $88.00 |
| Dec 9, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $94.00 |
| Dec 9, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $95.00 |
| Nov 5, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $81.00 |
| Nov 5, 2025 | Citizens | Jonathan Wolleben | Market Outperform | Maintains | $95.00 |
| Nov 5, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Maintains | $95.00 |
| Oct 16, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $81.00 |
| Sep 24, 2025 | TD Cowen | Joseph Thome | Buy | Initiates | $95.00 |
| Sep 12, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $77.00 |
| Aug 11, 2025 | Stifel | Dae Gon Ha | Buy | Reinstates | $89.00 |
| Aug 8, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $89.00 |
| Aug 7, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $82.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $80.00 |
| Aug 7, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $81.00 |
| May 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $73.00 |
| May 13, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $77.00 |
| May 9, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $76.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $72.00 |
| Feb 27, 2025 | Baird | Brian Skorney | Outperform | Maintains | $55.00 |
| Feb 24, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $74.00 |
Mirum Pharmaceuticals Inc. (MIRM) Competitors
The following stocks are similar to Mirum Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mirum Pharmaceuticals Inc. (MIRM) Financial Data
Mirum Pharmaceuticals Inc. has a market capitalization of $3.32B with a P/E ratio of -35.0x. The company generates $471.79M in trailing twelve-month revenue with a -8.8% profit margin.
Revenue growth is +47.2% quarter-over-quarter, while maintaining an operating margin of +2.0% and return on equity of -15.8%.
Valuation Metrics
Market Cap
$3.32B
Enterprise Value
$3.46B
P/E Ratio
-35.0x
PEG Ratio
0.3x
Price/Sales
7.2x
Growth & Margins
Revenue Growth (YoY)
+47.2%
Gross Margin
+80.8%
Operating Margin
+2.0%
Net Margin
-8.8%
EPS Growth
+47.2%
Financial Health
Cash/Price Ratio
+11.3%
Current Ratio
3.3x
Debt/Equity
109.1x
ROE
-15.8%
ROA
-3.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mirum Pharmaceuticals Inc. (MIRM) Business Model
About Mirum Pharmaceuticals Inc.
What They Do
Develops therapies for rare diseases.
Business Model
Mirum Pharmaceuticals Inc. generates revenue through the development and commercialization of innovative therapies specifically targeting rare diseases, particularly liver conditions. The company focuses on addressing unmet medical needs and works on facilitating regulatory approvals to ensure access to its treatments for patients.
Additional Information
Mirum is recognized for its contributions to conditions like Alagille syndrome, a rare genetic disorder. The company is dedicated to advancing research and improving the quality of life for patients with chronic illnesses, positioning itself as a vital player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
349
CEO
Mr. Christopher Peetz
Country
United States
IPO Year
2019
Website
www.mirumpharma.comMirum Pharmaceuticals Inc. (MIRM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 04, 2025
By Zacks Equity Research
Realtime BLOG
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
Dec 02, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Mirum Pharmaceuticals will acquire Bluejay Therapeutics for up to $820 million, gaining a late-stage experimental drug for severe liver disease.
Why It Matters
The acquisition enhances Mirum's pipeline with a potentially valuable drug, which could drive future revenues and influence stock performance positively.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Mirum Pharmaceuticals, Inc. discussed its M&A strategies during a recent call, outlining potential opportunities for growth and expansion in the pharmaceutical sector.
Why It Matters
The M&A call transcript for Mirum Pharmaceuticals indicates potential strategic moves, which could influence its stock price, market position, and future growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics, gaining rights to brelovitug, a late-stage antibody for chronic hepatitis delta virus, enhancing its rare disease portfolio.
Why It Matters
Mirum's acquisition of Bluejay Therapeutics enhances its pipeline with a promising HDV treatment, potentially increasing its market value and attracting investor interest in rare disease therapies.
Source: Business Wire
Market Sentiment:
Neutral
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
8 days ago
Quick Summary
Mirum Pharmaceuticals' Livmarli has seen significant success in 2025 and is expected to maintain growth momentum into 2026.
Why It Matters
Mirum Pharmaceuticals' success with Livmarli indicates strong revenue growth potential, positively impacting stock performance and attracting investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
8 days ago
Quick Summary
Mirum Pharmaceuticals, Inc. (MIRM) presented at the Evercore 8th Annual Healthcare Conference, sharing updates on their business and pipeline developments.
Why It Matters
Mirum Pharmaceuticals' presentation could signal new developments, partnerships, or financial outlooks, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Mirum has commenced its phase II BLOOM study by enrolling the first participant to investigate MRM-3379 as a treatment for Fragile X syndrome.
Why It Matters
Mirum's enrollment of the first participant in a key clinical trial for MRM-3379 could signal progress in treatment development, potentially impacting stock performance and market perception of the company.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About MIRM Stock
What is Mirum Pharmaceuticals Inc.'s (MIRM) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Mirum Pharmaceuticals Inc. (MIRM) has a median price target of $91.00. The highest price target is $95.00 and the lowest is $80.94.
Is MIRM stock a good investment in 2026?
According to current analyst ratings, MIRM has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $64.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIRM stock?
Wall Street analysts predict MIRM stock could reach $91.00 in the next 12 months. This represents a 40.7% increase from the current price of $64.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mirum Pharmaceuticals Inc.'s business model?
Mirum Pharmaceuticals Inc. generates revenue through the development and commercialization of innovative therapies specifically targeting rare diseases, particularly liver conditions. The company focuses on addressing unmet medical needs and works on facilitating regulatory approvals to ensure access to its treatments for patients.
What is the highest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The highest price target for MIRM is $95.00 from Michael Ulz at Morgan Stanley, which represents a 46.9% increase from the current price of $64.67.
What is the lowest forecasted price for MIRM Mirum Pharmaceuticals Inc.?
The lowest price target for MIRM is $80.94 from at , which represents a 25.2% increase from the current price of $64.67.
What is the overall MIRM consensus from analysts for Mirum Pharmaceuticals Inc.?
The overall analyst consensus for MIRM is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $91.00.
How accurate are MIRM stock price projections?
Stock price projections, including those for Mirum Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 3:27 AM UTC